Clinical Trials on Skin Melanoma

Total 51626 results

ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate

Melanoma (Skin)
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690

Melanoma (Skin)
Stanford University
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers

Melanoma, Skin

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

CCI-779 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States, Canada
University Hospital Erlangen

Completed

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

Germany
National Cancer Institute (NCI)

Completed

Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Duke University
National Cancer Institute (NCI)

Completed

Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg

Melanoma (Skin)

United States
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
Aurora Health Care

Terminated

Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
Mount Vernon Cancer Centre at Mount Vernon Hospital

Unknown

Carboplatin and Temozolomide in Treating Patients With Unresectable or Metastatic Melanoma

Melanoma (Skin)

United Kingdom
Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum...

Unknown

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

Germany
Beth Israel Deaconess Medical Center

Unknown

Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma

Melanoma (Skin)

United States
University of Illinois at Chicago
National Cancer Institute (NCI)

Completed

Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Beth Israel Deaconess Medical Center

Completed

Boron Neutron Capture Therapy in Treating Patients With Melanoma

Melanoma (Skin)

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
Iceland Genomics Corporation
National Cancer Institute (NCI)

Completed

Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members

Melanoma (Skin)

Iceland
Bristol-Myers Squibb
National Cancer Institute (NCI)

Withdrawn

Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma

Melanoma (Skin)
University of Alabama at Birmingham
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
European Organisation for Research and Treatment...

Terminated

Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

Germany
European Organisation for Research and Treatment...

Unknown

High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma

Melanoma (Skin)

France, Switzerland, Netherlands, Poland, Finland, Belgium, United Kingdom, Austria, Germany, Italy, Israel, Slovakia, Spain, Serbia, Portugal, Russian Federation, Bulgaria, Croatia, Turkey, Estonia, Sweden
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

France
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

Melanoma of Unknown Primary | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Metastatic Malignant Neoplasm in Lymph Node

United States
National Cancer Institute (NCI)
GlaxoSmithKline; Novartis Pharmaceuticals

Active, not recruiting

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Hematopoietic and Lymphoid Cell Neoplasm | Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable...

United States
M.D. Anderson Cancer Center

Active, not recruiting

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Melanoma | Metastatic Melanoma | Tumor

United States
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma (NADINA)

Malignant Melanoma Stage III

United States, Netherlands, Australia
University of Minnesota
Melanoma Research Alliance

Withdrawn

Pilot Study of Intervention to Reduce Sunburns in Melanoma Survivors

Melanoma (Skin)
University of California, San Francisco

Terminated

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

ALK Fusion Protein Expression | Stage III Cutaneous Melanoma | Stage IIIA Cutaneous Melanoma | Stage IIIB Cutaneous Melanoma | Stage IIIC Cutaneous Melanoma | Stage IV Cutaneous Melanoma | ROS1 Fusion Positive | BRAF wt Allele | Invasive Skin Melanoma | MET Fusion Gene Positive | NRAS wt Allele | NTRK1 Fusion... and other conditions

United States
Herlev Hospital

Enrolling by invitation

Safety and Avoidance of Futile Excisions Through Skin Tele-triage (SAFEST)

Telemedicine | Melanoma (Skin)

Denmark
National Human Genome Research Institute (NHGRI)
National Cancer Institute (NCI)

Completed

Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Completed

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Melanoma (Skin)

United States
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Completed

Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma

Melanoma (Skin)

United States
Jonsson Comprehensive Cancer Center
Pfizer

Completed

Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma

Melanoma (Skin)

United States
Jonsson Comprehensive Cancer Center
Pfizer

Completed

CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery

Melanoma (Skin)

United States
Louisiana State University Health Sciences Center...

Terminated

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
University of Wisconsin, Madison
National Cancer Institute (NCI)

Completed

Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma

Melanoma (Skin)

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); American Society of Clinical Oncology; Society...

Completed

Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma

Melanoma (Skin)

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim

Melanoma (Skin)
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma

Melanoma (Skin)

United States

Clinical Trials on Skin Melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations